Benzenemethanol, 4-hydroxy-alpha-(((3-(2-methoxyphenyl)-1,1-dimethylpropyl)amino)methyl)- | 72734-63-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Benzenemethanol, 4-hydroxy-alpha-(((3-(2-methoxyphenyl)-1,1-dimethylpropyl)amino)methyl)-
• 英文别名: 4-[1-hydroxy-2-[[4-(2-methoxyphenyl)-2-methylbutan-2-yl]amino]ethyl]phenol
• CAS: 72734-63-5
• 化学式: C₂₀H₂₇NO₃
• 分子量: 329.4
• InChiKey: QQNHGKXYJUREIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• A new system for administration of liposomes to mammals
  申请人：Aktiebolaget Draco

  公开号：EP0260241A1

  公开（公告）日：1988-03-16

  A new system to administer liposomal formulations to mammals, including man, comprising a dry lipid-based solid material, which in an aqueous milieu spontaneously form or reconstitute liposomes, and a device for aerosolizing a selected quantity of the lipid-based solid material in a suitable form, is described. The invention is particularily suitable for applications where the lipid-based solid composition is inhaled as a finely-divided powder in aerosol form and hydrated in the respiratory tract.

  本发明描述了一种对哺乳动物（包括人类）施用脂质体制剂的新系统，该系统包括一种在水环境中自发形成或重组脂质体的干燥脂基固体材料，以及一种以适当形式将选定数量的脂基固体材料气溶胶化的装置。 本发明特别适用于将脂基固体组合物作为气溶胶形式的细微粉末吸入并在呼吸道中水合的应用。
• Concentrated suspensions of drugs and their use to produce suspensions for inhalatory administration
  申请人：Eratech S.r.l.

  公开号：EP1683514A1

  公开（公告）日：2006-07-26

  Concentrated suspension of water insoluble pharmaceutical substances, comprising: a) micronized particles of at least one water insoluble pharmaceutical substance with a particle size distribution in which the d(0.5) fraction is less than 3 µm, the span value is less than 2, and such features are retained upon aging the suspension for 90 days; said pharmaceutical substance being present at a concentration of from 5 to 50 times the concentration of a suspension of the same substance for inhalatory administration; b) an aqueous solution of a pharmaceutically acceptable surfactant as dispersing medium for said micronized particles of pharmaceutical substance; c) a salt dissolved in said aqueous solution, at a concentration that: i) does not cause coagulation of said particles of pharmaceutical substance; and ii) generates upon dilution an inhalatory suspension in which the concentration of salt in the aqueous phase is not higher than 10 g/l. present at a concentration of from 0.1 to 2.0 g/l.

  不溶于水的药物浓缩悬浮液，包括 a) 至少一种水不溶性药物的微粉化颗粒，其粒度分布为 d(0.5) 部分小于 3 µm，跨度值小于 2，且悬浮液老化 90 天后仍能保持这些特征；所述药物的浓度为用于吸入给药的相同药物悬浮液浓度的 5 至 50 倍； b) 医药上可接受的表面活性剂的水溶液，作为所述药物微粒的分散介质； c) 溶于所述水溶液中的盐，其浓度为：i) 不会导致所述药物颗粒凝结；ii) 稀释后产生吸入悬浮液，其中水相中盐浓度不高于 10 克/升，浓度为 0.1 至 2.0 克/升。
• Ethanolamine compounds, processes for their preparation, pharmaceutical preparations containing them and their medicinal use
  申请人：Aktiebolaget DRACO

  公开号：EP0004835B1

  公开（公告）日：1981-10-14
• A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS
  申请人：Aktiebolaget Draco

  公开号：EP0282537A1

  公开（公告）日：1988-09-21
• COMPOSITIONS OF LIPOSOMES AND $g(b) 2?-RECEPTOR ACTIVE SUBSTANCES
  申请人：Aktiebolaget Draco

  公开号：EP0298984A1

  公开（公告）日：1989-01-18